Pharma BD Deal Intelligence
A licensing deal that ran its course and quietly closed: Lilly's up-to-$335M AXIRON pact, $50M upfront, peaked at $170.5M in 2014 sales and 13.7% share before the two sides terminated it in September 2017.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Trade-press coverage of Lilly acquiring the exclusive worldwide AXIRON license, described as the biggest-ever Australian biotech licensing arrangement at up to…
CosmeticsDesign-Asia framed the deal as Australian biotech Acrux securing a global commercialization partner for its differentiated underarm testosterone…
FDA confirmed Lilly requested withdrawal of the Axiron NDA in September 2017 and that the product was 'not withdrawn from sale for reasons of safety or…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Lilly entered exclusive worldwide license with Acrux for AXIRON: $50M upfront + $3M manufacturing transfer + $87M FDA marketing approval + $195M commercialization milestones, plus royalties.
$1.6B US testosterone replacement therapy market ~$1.6B in 2011
Male hypogonadism is a clinical syndrome of low serum testosterone (typically <300 ng/dL) plus symptoms — fatigue, low libido, decreased muscle mass, mood changes — caused by primary testicular failure, secondary pituitary/hypothalamic dysfunction, or age-related decline. Testosterone replacement therapy (TRT) restores serum levels via topical gels, solutions, transdermal patches, intramuscular injections, or buccal tablets.
The 2010 US TRT market was dominated by topical gels: AbbVie's AndroGel (testosterone 1% / 1.62%) was the runaway leader with ~$1B+ in annual sales, followed by Auxilium/Endo's Testim, Watson's Androderm transdermal patch, and Pfizer's Depo-Testosterone injection. The category was growing rapidly — TRT prescriptions rose with average annual percent change of ~15.5% from 2007-2014 [https://pmc.ncbi.nlm.nih.gov/articles/PMC7211140/] — driven by direct-to-consumer 'Low T' marketing campaigns. Axiron's strategic differentiation was the underarm (axillary) metered-dose applicator, which avoided the chest/abdomen application of competing gels and addressed AndroGel's chief weakness: secondary transfer to women and children, which prompted FDA boxed warnings on the gel category in 2009. Lilly paid $50M upfront plus $3M manufacturing transfer plus $87M FDA approval milestone plus up to $195M commercial milestones plus royalties — a structure heavily back-loaded. FDA approved Axiron November 23, 2010 [https://investor.lilly.com/news-releases/news-release-details/lilly-and-acrux-receive-fda-approval-axironr-testosterone]. Peak global sales reached $179M (2013) and $170.5M (2014) before declining sharply as the FDA's 2014-2015 cardiovascular safety label changes plus tort litigation collapsed the broader TRT category. Lilly voluntarily withdrew the Axiron NDA in 2017, with FDA confirming withdrawal effective July 2018.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Acrux Limited (AXIRON license) (this deal) | 2010 | $335M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2010 deals · Eli Lilly and Company deals · Metabolic deals